An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion
Open Access
- 3 March 2022
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-11
Abstract
Huntington’s Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin (HTT) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction, causing progressive motor, cognitive and behavioral abnormalities. Current treatments for HD only alleviate symptoms, but cerebral spinal fluid (CSF) or central nervous system (CNS) delivery of antisense oligonucleotides (ASOs) or virus vectors expressing RNA-induced silencing (RNAi) moieties designed to induce mHTT mRNA lowering have progressed to clinical trials. Here, we present an alternative disease modifying therapy the orally available, brain penetrant small molecule branaplam. By promoting inclusion of a pseudoexon in the primary transcript, branaplam lowers mHTT protein levels in HD patient cells, in an HD mouse model and in blood samples from Spinal Muscular Atrophy (SMA) Type I patients dosed orally for SMA (NCT02268552). Our work paves the way for evaluating branaplam’s utility as an HD therapy, leveraging small molecule splicing modulators to reduce expression of dominant disease genes by driving pseudoexon inclusion.Keywords
This publication has 32 references indexed in Scilit:
- Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's DiseaseHuman Gene Therapy, 2014
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- Energy deficit in Huntington disease: why it mattersJournal of Clinical Investigation, 2011
- Spliceosome Structure and FunctionCold Spring Harbor Perspectives in Biology, 2010
- Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD MiceThe Journal of Neuroscience, 2008
- Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAiProceedings of the National Academy of Sciences, 2008
- Longitudinal Evaluation of theHdh(CAG)150Knock-In Murine Model of Huntington's DiseaseJournal of Neuroscience, 2007
- RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse modelProceedings of the National Academy of Sciences, 2005
- Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington diseaseHuman Molecular Genetics, 2005
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993